Skip to main content

Biovest Takes 9 Percent Stake in MDxHealth

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today said that as part of its recent private placement, which brought in $11.7 million, investment firm Biovest has obtained a 9 percent stake in the company.

Biovest's president is Rudi Mariën, who is a co-founder and chairman of Innogenetics, a Belgium-based molecular diagnostics firm.

"The company has accomplished an impressive turnaround over the past 12 months, and is now pursuing a strategy that can sustainably generate novel, high value molecular cancer diagnostics," Mariën said in a statement.

MDxHealth completed the private placement earlier this month. It plans to use proceeds to accelerate the development of molecular diagnostic products, set up a CLIA laboratory, and hire a sales and marketing firm in the US.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.